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Abstract  
 
Background: Although multimorbidity has important implications for patient care in 
general practice, limited research has examined chronic illness and health service 
utilisation among problem drug users. This study aimed to determine chronic illness 
prevalence and health service utilisation among problem drug users attending primary 
care for methadone treatment, to compare these rates with matched ‘controls’ and to 
develop and pilot test a valid study instrument. 
 
Methods: A cross-sectional study of patients attending three large urban general 
practices in Dublin, Ireland for methadone treatment was conducted, and this sample 
was compared with a control group matched by practice, age, gender and General 
Medical Services (GMS) status.  
 
Results: Data were collected on 114 patients. Fifty-seven patients were on methadone 
treatment, of whom 52(91%) had at least one chronic illness (other then substance 
use) and 39(68%) were prescribed at least one regular medication. Frequent utilisation 
of primary care services and secondary care services in the previous six months was 
observed among patients on methadone treatment and controls, although the former 
had significantly higher chronic illness prevalence and primary care contact rates. The 
study instrument facilitated data collection that was feasible and with minimal inter-
observer variation.  
 
Conclusions: Multimorbidity is common among problem drug users attending general 
practice for methadone treatment. Primary care may therefore have an important role 
in primary and secondary prevention of chronic illnesses among this population. This 
study offers a feasible study instrument for further work on this issue. (238 words) 
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Background 
 
Injecting drug users have an increased mortality compared to the general population. 
Mortality rates of 13-30 per thousand persons per year (an age-adjusted mortality rate 
of 6.9-22.0) have been reported among injecting drug users, with opiate overdose and 
HIV infection the major causes of death [1-5].  
 
The introduction of ‘harm reduction’ interventions (ie interventions designed to 
prevent problems associated with problem drug use, eg oral methadone treatment, 
needle and injecting paraphernalia exchange programmes) has, in addition to 
advances in HIV treatment, been an important factor in reducing mortality / 
increasing life expectancy among problem drug users [6-8]. One might therefore 
expect an ‘epidemiological shift’, as chronic illnesses and their complications replace 
infectious diseases and drug overdose as causes of death. In this respect, an 
association between problem drug use and subsequent decrease in general self-rated 
health has been demonstrated [9].  
 
While bloodborne virus infections (in particular hepatitis C [10-12]), psychiatric 
illness [13] and to a lesser extent, problem alcohol use [14] are all recognised as 
chronic medical problems that are more prevalent among injecting drug users, our 
understanding of other ‘common’ chronic illnesses among injecting drug users is less 
advanced. While much is known about the epidemiology and management of 
diabetes, cardiovascular disease and chronic respiratory illness (eg asthma, COPD) 
and while the prevention and management of these chronic illnesses has been 
identified as a priority issue for population health in Ireland and globally [15, 16], no 
data have reported on the epidemiology or care of these illnesses among current or 
former drug users.  
 
The aims of this study were: 
- to determine chronic illness / multimorbidity prevalence and health service 
utilisation among problem drug users attending primary care for methadone 
treatment and to compare these rates with matched ‘controls’; 
- to develop and pilot test a valid study instrument. 
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Methods 
 
Setting 
 
The study was carried out in Dublin city, where an estimated 16.0 per thousand of the 
population currently use illicit opiates [17]. In Ireland, addiction treatment is currently 
provided by specialist addiction treatment services, including a central Drug 
Treatment Centre Board, regional addiction centres, community-based projects 
(satellite clinics) and by primary care. Most recent data reported that 7845 patients 
were treated for problem drug use by these agencies in 2002, with opiates the most 
common drug for which people attended for treatment (86% of total) [18].  
 
In recent years, the number of general practitioners (GPs) prescribing methadone has 
increased in Ireland, the UK and elsewhere in the EU [19-23]. To prescribe 
methadone in Ireland, GPs must complete special training and are subject to clinical 
audit, with GPs who provide methadone treatment for 15 or more patients subject to 
more regular audit and advanced training (‘level 2’ GPs) [24]. This system is 
analogous to the ‘GPs with a special interest’ (‘GPWsi’) model currently operating in 
the UK [25]. Initiation of methadone treatment is only permitted in specialist 
addiction clinics or by ‘level 2’ GPs [24]. In all other cases, chaotic opiate users are 
initially cared for in a specialist addiction clinic and their care then transferred to 
general practice when stable. In circumstances where illicit drug use of patients 
attending general practice becomes ‘chaotic’, addiction care is transferred to the 
specialist addiction services.  
 
The study was conducted in three large group general practices (see Table 1), all 
situated in areas of high deprivation and with practice populations predominantly 
eligible for General Medical Services (GMS) scheme (the scheme that at the time of 
the study provided free primary care services to approximately 30% of the Irish 
population on the basis of age over 70 years or low income). Each practice used both 
electronic and hard copy clinical records, but at the time of the study, each had been 
using electronic records alone for all new clinical and prescribing notes for at least 
six-months. Each practice was research-active and formally affiliated with one of 
Dublin’s three medical schools.  
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Subjects  
 
All patients attending each practice for methadone treatment on 1st July 2008 were 
eligible for the study. A considerable variability in numbers of patients attending the 
three practices for methadone existed at the time of the study, with 19 the smallest 
number of patients attending one of the practices for methadone treatment and hence 
19 cases were sampled at each practice.   
 
Sampling of ‘cases’: At each participating practice, the researcher and GP identified 
cases for inclusion in the study by random number sampling from a numbered list of 
patients attending that practice for methadone treatment (in Ireland, GPs are not 
allowed to issue a prescription for methadone for any more than two weeks and are 
remunerated on a ‘per consultation’ basis).  
 
Sampling of ‘controls’: Controls were matched for practice, age, GMS scheme 
membership and gender. Potential controls were identified by running a query of 
‘active patients’ registered on each practice’s electronic practice management 
information system using the matching criteria. This list of potential controls was then 
numbered and one control identified using random number sampling.  
 
Data collection and validation 
 
Data was collected from clinical records. A study instrument was developed for the 
purpose of this study (see Appendix 1). The instrument was based on another 
instrument routinely used to collect health information on current or former injecting 
drug users in Ireland, the Health Research Board National Drug Treatment Reporting 
System (NDTRS) [26]. Data were therefore collected on:  
• Demography 
• Addiction care  
• Chronic illnesses 
• Presentations with acute illnesses  
• Prescribing 
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• Health service utilisation (including: attendance at primary care, secondary 
care, out of hours services, emergency departments and diagnostic 
investigations). 
 
Data were collected by four researchers over the course of two weeks in July 2008: 
one researcher (SOB) collected data on all records and at each practice, one of the 
GPs at that practice (WC, FDOK or AOC) also collected data. Data was extracted 
from the ‘diagnosis’ ‘prescribing’, ‘consultation’, and ‘communication’ modules from 
individual electronic clinical records. In addition, paper records were reviewed for: 
‘active diagnoses / chronic illnesses’, and hospital referral / update / discharge letters.  
 
At consecutive intervals, the researchers compared the data collected to determine the 
degree of inter-observer variability; this check was conducted after six, 12, 19, 38 and 
57 records of patients on methadone had been reviewed. At each review, questions 
with an inter-observer agreement of less than 90% and questions where data 
extraction had proved problematic were revised and these revisions were incorporated 
into subsequent iterations of the study instrument. A log of the data collection process 
was maintained, with the amount of data collected in one three-hour sessional block 
and problems in data collection recorded.  
 
Data analysis 
 
Data were analysed using Statistical Packages for the Social Sciences (SPSS) version 
12.0. Analytical techniques included Pearson’s chi squared test to determine the 
significance of associations between categorical variables. Odds ratios and their 95% 
confidence intervals (CI) were used to compare rates of chronic and acute illness and 
health service utilisation between the two groups (cases and controls).  
 
Ethical considerations 
 
All data were collected and / or reviewed by a GP with clinical responsibility for the 
patient’s ongoing care. The strategy whereby GPs were involved in data collection 
was adopted for two reasons: to optimise data accuracy and in case any health issue 
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was identified that may require a subsequent clinical intervention. Any subsequent 
clinical interventions were not included in the data collection.  
 
The Irish College of General Practitioners Research Ethics Committee approved this 
study. We did not seek patient consent for review of clinical records by the researcher 
/ their GP. However, ethical safeguards included the following:  
- all data were collected anonymously and any details that could potentially 
identify individuals were removed after data collection;  
- all members of the research team were nominated as ‘agents’ of each practice 
and each signed a confidentiality agreement with the other participating 
practices. 
 
 
Results  
 
Feasibility and validity of data collection 
 
Data were collected on a sample of 114 patients attending three general practices: 57 
‘cases’ attending for methadone treatment (19 per practice) and 57 ‘controls’ (19 per 
practice) matched by practice, age, gender and GMS status. While considerable inter-
observer variation was apparent at the initial stages of data collection, this variation 
diminished as the study instrument was subsequently modified (See Table 2). For the 
final seven cases at Practice A, the two researchers disagreed on the answers to 2/36 
questions. In addition, later versions of the study instrument facilitated a more 
efficient data collection process that allowed one researcher to collect data on 19 
patients in three three-hour ‘sessions’ in the case of Practice B and two three-hour 
‘sessions’ in the case of Practice C.  
 
Demographic and addiction characteristics of patients on methadone treatment 
 
The mean age of ‘cases’ was 37.2 years (standard deviation: 7.25 years), 42(74%) 
were male, 41(72%) had GMS cover, all were Irish nationals and 56(98%) were 
documented as living in stable accommodation.  
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Considerable lifetime contact with the practice was observed: 16 patients (28%) had 
been attending the practice for less than 5 years, 21 patients (37%) for 5-10 years and 
20 patients (35%) for in excess of 10 years. Treatment of illicit drug use (20 patients), 
registration for general medical care (20 patients) and being referred by specialist 
addiction treatment services for methadone treatment (17 patients) were the reasons 
why patients had first attended (see Table 3). All patients that had been referred for 
methadone treatment by the specialist addiction treatment services had been with the 
practice for 10 years or less.  
 
Considerable contact with specialist addiction services (both lifetime and since 
commencing methadone treatment at the practice) was also observed among the 
sample. All patients had been prescribed methadone by specialist addiction services 
prior to attending the general practice for methadone treatment and 14(25%) patients 
had been referred back to specialist addiction services for methadone treatment since 
commencing methadone treatment at the practice (six in the previous year).  
 
The mean daily dose of methadone prescribed (on the last issued prescription) was 66 
milligrammes (standard deviation: 26 milligrammes). Tobacco / cigarette smoking 
status was recorded in the records of 39 patients (68% of total), of whom 37 were 
recorded as smokers.  
 
Morbidity among patients on methadone treatment 
 
Fifty-two patients (91%) had a chronic illness (in addition to substance / opiate / drug 
use) documented in their clinical record (mean chronic illnesses per patient: 2.6, 
standard deviation: 1.7). Table 4 indicates the number of patients with pre-determined 
chronic illnesses that were sought during the data collection and in the case of each, 
the number who had attended secondary care for that problem. Hepatitis C, 
depression, asthma and HIV / AIDS were the most common illnesses (38, 20, 14 and 
8 patients respectively). A wide range of chronic illnesses that had not been pre-
determined were also recorded among patients on methadone treatment. Of these 47 
chronic illnesses, back pain (5 patients), gastritis / chronic dyspepsia / gastro-
oesophageal reflux (4 patients) and DVT / varicose veins / thrombophlebitis (four 
patients) were the most common. Thirty-nine patients (68% of total) were on regular 
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prescribed medication, in addition to methadone, (mean medications per patient: 2.4, 
standard deviation: 3.0). 
 
Thirty-one patients (54%) had an acute illness during the previous three-months,  
(mean acute illnesses per patient: 1.0, standard deviation: 1.5). Upper respiratory tract 
infection (10 patients), sleep disturbance / anxiety / feeling depressed (four), 
abdominal pain (four), urinary tract infection (three) and ear wax (three) were the 
most commonly documented acute illnesses.   
 
Twenty-five patients (44% of total) had been prescribed at least one time-limited 
medication (in addition to methadone) for the treatment of an acute illness during the 
previous three months (mean medications per patient: 0.9, standard deviation: 1.5). 
 
Health service utilisation among patients on methadone treatment 
 
In the previous six months, patients on methadone had attended their GP for issues 
other than their addiction care a mean of 3.9 times (standard deviation: 4.1), and had 
attended another healthcare professional in the practice a mean of 0.5 times (standard 
deviation: 0.8). Three patients had used the out of hours services provided by the 
practice and ten patients (18%) had at least one diagnostic investigation arranged or 
performed by the practice. A total of 23 such investigations were performed on these 
ten patients, which included: biochemistry / haematology (13), microbiology (six), 
cervical smears (three) and radiology (one).  
 
In the previous six months, 27 patients (47%) had either been referred to, or attended 
secondary care, with Emergency Department (10 referrals / attendances), infectious 
diseases (10 referrals / attendances), gastroenterology (8 referrals / attendances), 
hepatology (6 referrals / attendances), addiction services (4 referrals / attendances) 
and psychiatry (3 referrals / attendances) the secondary care services to which patients 
were most commonly referred / attended.    
 
Comparison with ‘control’ group 
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The mean age of ‘controls’ was 37.2 years (standard deviation: 0.44), 42(74%) were 
male, 41(72%) had GMS cover and all were Irish nationals. Thirty-eight (67%) were 
documented as living in stable accommodation.  
 
Among the ‘control’ group (n=57), morbidity and health service utilisation rates were 
also high, with 40(70%) having a documented chronic illness and 23(40%) being 
prescribed recurrent medications. In the previous six months, 27(47%) had consulted 
with a healthcare professional at the practice, 19(33%) were referred to secondary 
care and 11(19%) had investigations performed by the practice. In the previous three 
months, 21(37%) had attended with an acute illness.  
 
Table 4 highlights a lower prevalence of psychological illness, bloodborne virus 
infection and respiratory illness among ‘controls’. Table 5 compares morbidity and 
health service utilisation characteristics of patients on methadone with controls. 
Patients attending for methadone treatment were significantly more likely to have a 
chronic illness, to be prescribed recurrent medications and to consult with a GP or 
other healthcare professional at the practice. Although they were also more likely to 
have attended with and be prescribed medication for acute illnesses and to have been 
referred to secondary care, these differences were not statistically significant.  
 
 
Discussion  
 
Key findings 
 
The proportions of cases (patients on methadone) and controls that had a chronic 
illness, that were prescribed regular medication, that attended with acute illnesses and 
that consulted with primary / secondary care were high, although patients on 
methadone treatment were more likely to have at least one chronic illness recorded, to 
be prescribed regular medications and to have attended primary care.    
 
Methodological considerations 
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Validity of the data reported in this paper is likely to have been enhanced by the 
practices in which it was conducted (research-active, with advanced practice 
information systems) and the method of data collection (two researchers validating 
and cross-checking data that had been extracted and a study instrument developed to 
minimise variation between researchers).  
 
However, we acknowledge a number of potential sources of bias. Participating 
practices had a longstanding clinical and research interest in problem drug use. While 
not representative of practices providing methadone treatment in Dublin, we 
considered them an appropriate environment for exploratory research on this subject.  
 
Ascertainment bias is also possible as patients on methadone must attend their GP 
every 1-2 weeks in Ireland [24]. As data were collected from clinical records, it is 
possible that frequent attendance (for methadone treatment) may increase 
documentation of chronic illnesses. It is also possible that this review of clinical 
records may have under / over reported other behaviours such as smoking. Selection 
bias was also possible, as patients with less severe and extreme problem drug use do 
not attend general practice for methadone treatment in Ireland.  
 
Such considerations notwithstanding, the sample was comparable to larger samples of 
patients attending general practice for methadone treatment in Ireland in terms of 
gender and bloodborne virus status, but was older [27, 28].  
 
How this relates to other literature 
 
Work conducted in a similar setting to ours has identified a number of barriers to 
multimorbidity research and these include: problems with practice software, 
variations in disease coding and accurately determining primary and secondary care 
activity through clinical records [29]. While our experience would support these 
barriers and while morbidity data extracted from clinical records will inevitably be 
determined by clinical record keeping, we suggest that adopting a study instrument 
that is already being used in primary care [26] and modifying this to minimise inter-
observer variation, can yield consistent data across practices.  
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Our findings regarding multimorbidity and chronic illness among patients on 
methadone treatment are consistent with North American studies that have reported 
higher prevalence of medical and psychiatric conditions among problem substance 
users [30, 31]. Our findings regarding health service utilisation is consistent with 
other work which show illicit drug users more likely to use Emergency Department 
and primary care [32].  
 
While chronic respiratory disease may not yet be widely recognised as such, this 
study highlights the potential importance of its prevention and treatment among 
problem drug users. We anticipated the prevalence of other chronic illnesses (eg 
chronic alcohol abuse, diabetes, hypertension, ischemic heart disease) might have 
been higher and reasons for this and incidence rates should be explored in further 
research, especially as the cohort ages. In time, it is possible that adverse lifestyle 
factors will increase the incidence of these chronic illnesses, thereby leading to more 
complex care.  
 
This study has also documented a high prevalence of chronic illness, incidence of 
acute illness and high contact rates with primary / secondary care among ‘controls’, 
findings which may be explained by the study being conducted in areas of high 
deprivation [33].   
 
Implications for research and clinical practice 
 
This pilot study has highlighted a need for further research on the epidemiology of 
chronic illnesses among patients on methadone. A larger, more representative sample 
of practices would make for more generalisable findings regarding illness prevalence. 
Conducting such research at practices from a range of socio-economic areas would 
allow controlling for deprivation as a potential confounder. Longitudinal studies 
would enable determination of incidence of key chronic illnesses, with data being 
collected directly from patients as well as from clinical records.  
 
Such research should explore opportunities for primary and secondary prevention of 
chronic illness and determine uptake of primary care interventions in chronic illness 
management.  
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In this pilot study, a 21% difference in chronic illness prevalence rates between 
‘cases’ and ‘controls’ was documented. However, chronic illness prevalence rates 
among problem drug users and ‘controls’ may have been higher in our study for 
reasons discussed above. Allowing for a more conservative estimate of chronic illness 
prevalence among (general) young adult populations of 48% [34], a 21% difference 
among problem drug users, we estimate data on 86 patients on methadone and 86 
controls would determine a statistically significant difference in chronic illness 
prevalence rates (assuming significance of 0.05, power of 0.90 and a case:control 
ratio of 1:1).     
 
If the findings of this pilot study are supported by more powerful / representative 
studies, then screening and treatment of chronic illness and increasing care 
complexity will be important issues in the future management of problem drug users. 
Therefore, an integrated care model, in which primary care and addiction care both 
care for problem drug users may best address this population’s health needs [35].  
 
Conclusions 
Multimorbidity is common among problem drug users attending general practice for 
methadone treatment, and primary care may have an important role in primary and 
secondary prevention of chronic illnesses among this group. Further work on chronic 
illness and health service utilisation among problem drug users is advocated and this 
study offers a feasible study instrument. 
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Appendix 1. Final draft of study instrument 
 
A. Administrative details 
 
HSE area of practice 
East Coast 
Northern  
South western 
Southern 
NW 
Midland 
Western 
Mid western 
NE 
 
Type of addiction treatment 
 
Being prescribed methadone at present:  Yes    No  
 
Primary agency managing addiction problem: GP    Addiction clinic 
 
Client number ____________(Note deleted from final electronic file)  
 
B. Demography 
 
Gender      Male   Female 
 
Age last birthday 
 
DOB 
 
Health cover    GMS   Non-GMS 
 
GMS number (Note deleted from final electronic file) 
 
Living where 
Stable accommodation 
Institution 
Homeless 
Other  
Not Known 
 
Area of residence 
DED    ______________ 
 
CCA    ______________ 
 
County registration plate  ______________ 
 
ationality     
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Irish 
Irish traveller 
Other  
Not known 
 
C. D. E. Addiction care details  
 
Date first referred to / attended general practice _____________ 
 
Main reason for first referral / attendance (tick)  
Alcohol use 
Illicit drug use 
Licit drug use 
Referred by specialist addiction services for methadone treatment 
General medical care / GMS registration 
Other 
 
Was the patient prescribed methadone by any other agency / clinic before attending 
the practice for methadone treatment:  
 
Yes  No 
 
What is the earliest recorded date on which the patient was prescribed methadone by 
any agency / clinic (01/month/year)   _____________ 
 
What is the earliest recorded date on which the patient was prescribed methadone at 
this practice (01/month/year)     _____________ 
 
Has the patient attended any other agency / clinic for addiction treatment since the 
above date (21b)?     
Yes  No 
 
Has the patient attended any other agency / clinic for addiction treatment in the last 12 
months?  
       Yes  No 
 
Date last treatment episode with methadone commenced _____________ 
 
Dose of methadone at last prescription _________MILLIGRAMMES PER DAY 
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F. Chronic disease 
 
Which illnesses that require ongoing follow up have been documented at the time of 
data being collected and / or at any time in the past and in the case of each has patient 
attended secondary care for this problem 
- Diabetes –Insulin Dependent (T90) 
- Diabetes – Non Insulin Dependent (T91) 
- Cardiac arrhythmia (K80) 
- Rheumatic fever (K71) 
- Ischaemic heart disease with angina (K74) 
- Acute myocardial infarction (K75) 
- Ischaemic heart disease (K76) 
- Heart failure (K77) 
- Pulmonary heart disease (K82) 
- Heart valve disease (K83) 
- Heart disease other (K84) 
- Hypertension complicated (K87) 
- Asthma (R96) 
- Chronic obstructive pulmonary disease (R95) 
- Depression (P76) 
- Viral hepatitis (D72): hepatitis C 
- Viral hepatitis (D72): hepatitis B 
- HIV / AIDS (B90) 
- Anxiety Disorder (P74) 
- Chronic alcohol abuse (P15) 
- Other chronic illnesses 
 
Documented acute illnesses in the preceding 3 months (and their ICPC-2 code) 
 
If the patient attended today for a repeat prescription, what medication would be 
prescribed? Medication (generic name) / route 
 
Acute / non-recurrent medications in the last 3 months: medication (generic name) / 
route 
 
In the last 6 months, number of consultations (excluding those concerning ONLY 
methadone) with: 
- a doctor in the practice:     ____________ 
- another healthcare professional in the practice: ____________ 
 
Has patient been referred to or attended secondary care (including emergency 
departments) in the last 6 months?  
       Yes   No 
If yes, please specify: specialty / date referred by practice / date attended specialty 
 
Has patient attended out of hours / GP deputising service in the last 6 months?  
       Yes   No 
 
If yes, please specify: Date / Problem / ICPC code 
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Has patient had a diagnostic investigation arranged / performed by the practice in the 
last 6 months (excluding urine toxicology)?   Yes   No 
 
If yes, please specify: pathology / diagnostic imaging / other 
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Tables 
 
Table 1. Characteristics of practices that participated in study.  
Practice Description Approximate 
number of patients 
on  methadone 
treatment at 
practice  
Clinical records  
A  3.0 FTE doctor 
teaching general 
practice in Dublin’s 
south inner city 
19 Combined electronic / 
paper 
B  Four doctor teaching 
general practice in 
Dublin’s south inner 
city 
45 Combined electronic / 
paper 
C  2.5 FTE general 
practice in Dublin’s 
north inner city 
70 Combined electronic / 
paper 
 
 
Table 2. Description of data collection process from clinical records of patients being 
prescribed methadone.   
Workload (in number of three-hour sessions) 
involved in data collection to collect data  
Practice  Clinical 
records 
Items with inter-
observer 
disagreement/total Lead researcher  GP researcher 
A 1-6 14/32 2.0 1.0 
 7-12 7/34 1.5 1.0 
 13-19 2/36 1.0 0.5 
B 20-38 0/39 3.0 0.5 
C 39-57 0/39 2.0 0.3 
 
 
Table 3. Reasons why, and time since, patients on methadone first attended practice.  
Reason first attended 
practice 
First attended the 
practice <10 years 
ago 
First attended the 
practice >10 
years ago 
Total 
Treatment of illicit 
drug use 
11 9 20 
Referred by 
addiction services 
for methadone 
treatment 
17 0 17 
General medical care 9 11 20 
Total 37 20 57 
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Table 4. Prevalence of, and attendance at secondary care for specific chronic illnesses 
same.  
Chronic illness (ICPC code) Number of patients with 
illness documented / 
number who have 
attended secondary care 
for this illness (cases) 
 ‘Cases’ ‘Controls’ 
Diabetes –Insulin Dependent (T90) 1/1 0/0 
Diabetes – Non Insulin Dependent (T91) 1/1 1/0 
Heart valve disease (K83) 1/1 0/0 
Asthma (R96) 14/1 6/1 
Chronic obstructive pulmonary disease (R95) 2/1 0/0 
Depression (P76) 20/14 6/2 
Viral hepatitis (D72): hepatitis C 38/24 1/0 
Viral hepatitis (D72): hepatitis B 6/4 2/1 
HIV / AIDS (B90) 8/8 1/1 
Anxiety Disorder (P74) 2/1 1/1 
Chronic alcohol abuse (P15) 5/0 0/0 
Other chronic illnesses documented 47/27 52/27 
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Table 5. Patients attending for methadone treatment compared to randomly sampled 
population matched by practice, age, gender and GMS cover.  
 
 Patients on 
methadone 
Randomly 
sampled 
control 
population 
Odds ratio 
(95% 
confidence 
interval)  
Chi squared 
(p value) 
Chronic illness 52/57 40/57 4.4(1.5-13.0) 8.11(<0.005) 
On recurrent 
medications 
39/57 23/57 3.2(1.5-6.9) 9.05(<0.005) 
Attendance with 
acute illness a 
31/57 21/57 2.0(1.0-4.3) 3.54(0.06) 
Medication 
prescribed for 
acute illness a 
25/57 15/57 2.2(1.0-4.8) 3.85(0.05) 
Attended GP / 
healthcare 
professional at 
practice b 
45/57 27/57 4.2(1.8-9.5) 12.2(<0.001) 
Referred to / 
attended 
secondary care b 
27/57 19/57 1.8(0.8-3.8) 2.33(0.13) 
Attended 
practices’ out of 
hours / 
deputising 
service b 
3/57 5/57 0.6(0.1-2.5) 0.54(0.46) 
Has had 
investigations 
performed / 
arranged by 
practice b 
10/57 11/57 0.9(0.3-2.3) 0.06(0.81) 
 
a in previous 3 months; b in the previous 6 months.  
